Advances in the development of new vaccines for tuberculosis and Brazil's role in the effort forward the end TB strategy.

IF 2.5 4区医学 Q2 PARASITOLOGY

Memorias do Instituto Oswaldo Cruz Pub Date : 2024-10-04 eCollection Date: 2024-01-01 DOI:10.1590/0074-02760240093

Ana Paula Junqueira-Kipnis, Luciana Cesar de Cerqueira Leite, Júlio Croda, Erica Chimara, Anna Cristina C Carvalho, Ricardo Alexandre Arcêncio

{"title":"Advances in the development of new vaccines for tuberculosis and Brazil's role in the effort forward the end TB strategy.","authors":"Ana Paula Junqueira-Kipnis, Luciana Cesar de Cerqueira Leite, Júlio Croda, Erica Chimara, Anna Cristina C Carvalho, Ricardo Alexandre Arcêncio","doi":"10.1590/0074-02760240093","DOIUrl":null,"url":null,"abstract":"<p><p>Tuberculosis (TB) continues to be the world's leading killer of infectious diseases. Despite global efforts to gradually reduce the number of annual deaths and the incidence of this disease, the coronavirus disease 19 (COVID-19) pandemic caused decreased in TB detection and affected the prompt treatment TB which led to a setback to the 2019 rates. However, the development and testing of new TB vaccines has not stopped and now presents the possibility of implanting in the next five years a new vaccine that is affordable and might be used in the various key vulnerable populations affected by TB. Then, this assay aimed to discuss the main vaccines developed against TB that shortly could be selected and used worldwide, and additionally, evidence the Brazilian potential candidates' vaccines in developing in Brazil that could be considered among those in level advanced to TB end.</p>","PeriodicalId":18469,"journal":{"name":"Memorias do Instituto Oswaldo Cruz","volume":"119 ","pages":"e240093"},"PeriodicalIF":2.5000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452070/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Memorias do Instituto Oswaldo Cruz","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1590/0074-02760240093","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PARASITOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Tuberculosis (TB) continues to be the world's leading killer of infectious diseases. Despite global efforts to gradually reduce the number of annual deaths and the incidence of this disease, the coronavirus disease 19 (COVID-19) pandemic caused decreased in TB detection and affected the prompt treatment TB which led to a setback to the 2019 rates. However, the development and testing of new TB vaccines has not stopped and now presents the possibility of implanting in the next five years a new vaccine that is affordable and might be used in the various key vulnerable populations affected by TB. Then, this assay aimed to discuss the main vaccines developed against TB that shortly could be selected and used worldwide, and additionally, evidence the Brazilian potential candidates' vaccines in developing in Brazil that could be considered among those in level advanced to TB end.

查看原文本刊更多论文

开发新的结核病疫苗的进展情况以及巴西在努力推进根除结核病战略中的作用。

结核病（TB）仍然是世界上最主要的传染病杀手。尽管全球都在努力逐步减少结核病的年死亡人数和发病率，但冠状病毒病 19（COVID-19）大流行导致结核病检测率下降，影响了结核病的及时治疗，从而使 2019 年的结核病发病率倒退。然而，新型结核病疫苗的开发和测试并未停止，现在有可能在未来五年内植入一种负担得起的新型疫苗，并可用于受结核病影响的各种主要易感人群。因此，本研究旨在讨论短期内可在全球范围内选择和使用的主要结核病疫苗，并证明巴西正在开发的潜在候选疫苗，这些疫苗可被考虑用于结核病的晚期治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Memorias do Instituto Oswaldo Cruz 医学-寄生虫学

CiteScore

5.00

自引率

3.60%

发文量

审稿时长

3-8 weeks

期刊介绍： Memórias do Instituto Oswaldo Cruz is a journal specialized in microbes & their vectors causing human infections. This means that we accept manuscripts covering multidisciplinary approaches and findings in the basic aspects of infectious diseases, e.g. basic in research in prokariotes, eukaryotes, and/or virus. Articles must clearly show what is the main question to be answered, the hypothesis raised, and the contribution given by the study. Priority is given to manuscripts reporting novel mechanisms and general findings concerning the biology of human infectious prokariotes, eukariotes or virus. Papers reporting innovative methods for diagnostics or that advance the basic research with these infectious agents are also welcome. It is important to mention what we do not publish: veterinary infectious agents research, taxonomic analysis and re-description of species, epidemiological studies or surveys or case reports and data re-analysis. Manuscripts that fall in these cases or that are considered of low priority by the journal editorial board, will be returned to the author(s) for submission to another journal.